Quick Answer
Aspire Biopharma Holdings, Inc. reported Operating Income Loss of -$19.35 million for the year ending 2025.
- Aspire Biopharma Holdings, Inc. showed a decrease of -1,498.1% in Operating Income Loss from 2024 to 2025.
- This data is from Aspire Biopharma Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2024 to 2025 (2 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2024: -$215.3 thousand | Q3 2025: -$1.15 million.
- Historical annual values: Fiscal year 2025: -$19.35 million | Fiscal year 2024: -$1.21 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: